

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Nanjing Leads Biolabs Co., Ltd.**  
**南京维立志博生物科技股份有限公司**

*(A joint stock company established in the People's Republic of China with limited liability)*

**(Stock Code: 9887)**

**DATE OF BOARD MEETING**

The board (the “**Board**”) of directors (the “**Directors**”) of Nanjing Leads Biolabs Co., Ltd. (the “**Company**”) hereby announces that a meeting of the Board will be held on Friday, 27 March 2026 for the purposes of, among other things, considering and approving the annual results of the Company and its subsidiaries for the year ended 31 December 2025 and its publication, and considering the recommendation on the payment of a dividend, if any.

By order of the Board  
**Nanjing Leads Biolabs Co., Ltd.**  
南京维立志博生物科技股份有限公司  
**Dr. KANG XIAOQIANG**  
*Chairman, Executive Director and  
Chief Executive Officer*

Hong Kong, 17 March 2026

*As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Ni Jia as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.*